The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy
- 1 July 1985
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 29 (3), 154-157
- https://doi.org/10.1002/jso.2930290304
Abstract
The effect of known chemotherapeutic programs in patints with breast cancer who developed metastasis during or after adjuvant chemotherapy with L-PAM plus 5-FU (PF) were switched. Thirteen patients failed while receiving adjuvant therapy at 3–22 months from the time therapy started. Three patients failed 6–28 months after 2 year of therapy. Thirteen patients received PF followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) at the time of progression PF. Of these, ten received Adriamycin and vincristine (AV) at the time of progression on CMF. The response to CMF was 7%. No patint responded to AV after progression on CMF. Two of three patients treated with AV after failure on PF did respond, but both for only 6 responsive to further chemotherapy. Sine most patients failed while on adjuvant therapy, this may indicate a poor prognosis regardless of the agents used.Keywords
This publication has 4 references indexed in Scilit:
- Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapyCancer, 1983
- Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimensCancer, 1981
- L-phenylalanine mustard (L-PAM) in the management of primary breast cancer:An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU)Cancer, 1977
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerNew England Journal of Medicine, 1976